EUVIMEDEUVIMED entdecken
Open Access

Economic evaluation of stapokibart for chronic rhinosinusitis with nasal polyps in China: a cost–effectiveness analysis

Jingran Yang iD, Lei Ren, Fengyuan Xie iD, Rong Shao, Rong Jiang iD

Journal of Comparative Effectiveness Research · 2026-06 · 15 (6)

DOI: 10.57264/cer-2025-0189 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Comparative Effectiveness Research, 2026-06. Verfasst von Jingran Yang und 4 weiteren Autor:innen. Beteiligte Einrichtung: School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing, China. Hauptthemen laut MEDLINE: Rhinosinusitis, Nasal Polyps, Antibodies, Monoclonal, Humanized, Sinusitis. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

To evaluate the cost–effectiveness of stapokibart compared with dupilumab in treating chronic rhinosinusitis with nasal polyps (CRSwNP) from the healthcare system perspective in China. The focus is on assessing the economic viability of biologic treatments in managing CRSwNP, particularly when conventional treatments and/or surgery fail to provide sufficient relief. Materials & methods: A decision tree Markov model was developed to assess the cost–effectiveness of stapokibart and dupilumab. Clinical data from multiple trials were used, and a matching-adjusted indirect comparison was conducted to account for differences in patient populations across studies. Sensitivity analysis was performed to evaluate the robustness of the model results under varying assumptions.

Results

The study results indicate that stapokibart offers a clear economic advantage over dupilumab. It both lowers treatment costs and enhances patients' quality of life. Sensitivity analysis shows that stapokibart remains cost-effective at the threshold of one to three-times China’s per capita GDP, demonstrating strong economic viability in the Chinese healthcare context.

Conclusion

The study demonstrates that stapokibart is a cost-effective treatment option for CRSwNP compared with dupilumab. It offers significant improvements in patient outcomes and is economically viable under the prevailing healthcare budget in China, providing valuable insights for policy-makers and healthcare providers.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RhinosinusitisNasal PolypsAntibodies, Monoclonal, HumanizedSinusitisRhinitisHumansCost-Benefit AnalysisCost-Effectiveness AnalysisChinaChronic DiseaseMarkov ChainsDecision TreesQuality of Life

Stichwörter der Autor:innen

chronic rhinosinusitiscost–effectivenessdupilumabnasal polypsstapokibart

Substanzen

Antibodies, Monoclonal, Humanizeddupilumab

Autor:innen und Institutionen

  • School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing, China.
  • Faculty of Pharmacy, Naval Medical University, Shanghai, China.

ORCID-Profile: Jingran Yang, Fengyuan Xie, Rong Jiang

Zitieren

APA

Yang, J., Ren, L., Xie, F., Shao, R., & Jiang, R. (2026). Economic evaluation of stapokibart for chronic rhinosinusitis with nasal polyps in China: a cost–effectiveness analysis. Journal of Comparative Effectiveness Research, 15(6). https://doi.org/10.57264/cer-2025-0189

Vancouver

Yang J, Ren L, Xie F, Shao R, Jiang R. Economic evaluation of stapokibart for chronic rhinosinusitis with nasal polyps in China: a cost–effectiveness analysis. Journal of Comparative Effectiveness Research. 2026;15(6). doi:10.57264/cer-2025-0189

BibTeX
@article{Yang2026,
  author = {Yang, Jingran and Ren, Lei and Xie, Fengyuan and Shao, Rong and Jiang, Rong},
  title = {Economic evaluation of stapokibart for chronic rhinosinusitis with nasal polyps in China: a cost–effectiveness analysis},
  journal = {Journal of Comparative Effectiveness Research},
  year = {2026},
  volume = {15},
  number = {6},
  doi = {10.57264/cer-2025-0189}
}
Kostenlos starten →